• NF 340: Selective P2Y11 Antagonist for GPCR Pathway Research

  2026-07-08

  NF 340 is a potent, selective P2Y11 antagonist used in immunology and cancer research to dissect GPCR signaling pathways. Its targeted inhibition of P2Y11 enables precise modulation of inflammation and cell migration mechanisms, as validated in recent peer-reviewed studies.

• QPRT Drives Breast Cancer Invasion via P2Y11-Mediated Signal

  2026-07-08

  The reference study identifies quinolinate phosphoribosyltransferase (QPRT) as a key promoter of breast cancer invasiveness through its impact on myosin light chain phosphorylation, mediated by purinergic signaling. Pharmacological inhibition using a P2Y11 antagonist, such as NF 340, reversed these effects, providing novel mechanistic and experimental insights for researchers studying cancer progression.

• OM-MSCs Mitigate GA Stress via PEDF-PI3K/Akt/mTOR in Stroke

  2026-07-07

  This study reveals how olfactory mucosa mesenchymal stem cells (OM-MSCs) attenuate Golgi apparatus (GA) stress after cerebral ischemia/reperfusion injury by activating the PEDF-PI3K/Akt/mTOR pathway. The findings provide mechanistic insight into the neuroprotective effects of OM-MSCs and highlight the significance of targeting GA stress responses in stroke therapeutics.

• Fucoidan Mitigates Irinotecan-Induced Steatohepatitis via Gu

  2026-07-07

  The referenced study uncovers how fucoidan counters irinotecan (CPT-11)-induced steatohepatitis by restoring gut barrier function and suppressing hepatic neutrophil extracellular trap (NET) formation. These findings highlight a mechanistic link between the gut–liver axis, chemotherapy-induced liver injury, and the potential of barrier-targeted interventions for improving cancer therapy tolerance.

• In Vitro Drug Response Metrics: Advances for VEGFR Inhibitor

  2026-07-06

  Schwartz's dissertation fundamentally redefines how in vitro drug responses are evaluated by distinguishing between proliferative arrest and cell death in anti-cancer assays. This methodological advance enables more precise interpretation of agent efficacy in oncology research, such as with VEGFR-targeted inhibitors.

• miR-24-3p/Sp1/PI3K Axis in Doxorubicin-Induced Heart Failure

  2026-07-06

  This study elucidates how miR-24-3p exacerbates cardiac dysfunction in doxorubicin-induced heart failure by directly suppressing the Sp1/PI3K signaling pathway. Silencing miR-24-3p was shown to mitigate apoptosis and oxidative stress, unveiling a new therapeutic target for cardiac injury research.

• Co-Targeting BCL-xL and MCL-1 Induces Lethal Apoptosis in Me

  2026-07-05

  Xu et al. reveal that simultaneous inhibition of anti-apoptotic proteins BCL-xL and MCL-1 triggers rapid, synergistic mitochondrial dysfunction and cell death in diffuse mesothelioma models. The findings clarify the redundancy and compensatory mechanisms of Bcl-2 family proteins, informing safer, more effective strategies for overcoming therapeutic resistance in this aggressive cancer.

• Trelagliptin Succinate: Rethinking Type 2 Diabetes Research

  2026-07-04

  Explore the mechanistic depth and translational promise of Trelagliptin succinate (SYR-472 succinate) as a once-weekly, selective DPP-4 inhibitor. This article advances the scientific dialogue beyond routine product bulletins by integrating validated biological pathways, rigorous analytical standards, and strategic guidance for researchers seeking robust, reproducible results in type 2 diabetes and related metabolic research.

• Strategic Deployment of MK-1775 in Translational Oncology

  2026-07-03

  Explore the mechanistic underpinnings and translational promise of MK-1775 (Wee1 kinase inhibitor) as a catalyst for cell cycle checkpoint abrogation and chemosensitization in p53-deficient cancer research. This thought-leadership article unpacks the latest insights, protocol guidance, and future directions for leveraging APExBIO's MK-1775 in advanced in vitro and in vivo workflows, anchored by emerging doctoral research and comparative literature.

• NF 340: Dissecting P2Y11 Antagonism in Cancer Metastasis Mod

  2026-07-03

  Explore how the P2Y11 antagonist NF 340 enables advanced investigation of purinergic signaling in cancer metastasis. This article delivers a uniquely detailed, evidence-based guide to integrating NF 340 into translational assays, with insights not found in existing content.

• SD 169 (indole-5-carboxamide): Precision p38 MAPK Inhibition

  2026-07-02

  SD 169 (indole-5-carboxamide) enables dual-action, highly selective inhibition of p38α/β MAPK, with quantified efficacy in both type 1 diabetes and neuroregeneration models. Discover stepwise protocols, troubleshooting strategies, and how the latest structural insights empower more reproducible and sensitive kinase pathway modulation.

• Phosbind Acrylamide: Advancing Viral Kinase Phosphorylation

  2026-07-02

  Explore how Phosbind Acrylamide transforms protein phosphorylation analysis in viral kinase research. This article uniquely bridges advanced phosphate-binding reagent workflow with insights from contemporary innate immunity studies.

• Spectral Cytometry Reveals Immune Effects of Ruxolitinib-oHS

  2026-07-01

  This study leverages high-dimensional spectral flow cytometry to characterize immune modulation in murine sarcoma following combined ruxolitinib and oncolytic HSV therapy. The findings reveal expanded CD4+ T cell activity and germinal center B cell populations, underscoring new mechanistic avenues for immunomodulation in myeloproliferative and solid tumor research.

• Fumagillin’s Translational Spectrum: From Angiogenesis to An

  2026-07-01

  Explore Fumagillin as a potent methionine aminopeptidase-2 inhibitor with dual relevance in cancer and antiparasitic research. This deep-dive reveals unique mechanistic insights and practical protocol guidance not found in existing articles.

• SERCA Inhibition by BHQ Enhances HSC Mobilization via ER Str

  2026-06-30

  Li et al. (2025) demonstrate that selective inhibition of SERCA using 2,5-di-tert-butylbenzene-1,4-diol (BHQ) induces mild endoplasmic reticulum (ER) stress, significantly enhancing hematopoietic stem cell (HSC) mobilization in vivo. This mechanistic insight into the CaMKII-STAT3-CXCR4 pathway offers new potential strategies for improving the efficacy of stem cell transplantation.

15054 records 1/1004 page Next 12345 下5页 Last page